Smart Drug Research Articles

Stimuli-Responsive Nano/Biomaterials for Smart Drug Delivery in Cardiovascular Diseases: Promises, Challenges and Outlooks

Cardiovascular Diseases (CVDs) are responsible for the highest number of deaths and disabilities globally. Although numerous therapeutic options exist for treating CVDs, most traditional strategies have proven ineffective in halting or significantly slowing disease progression, often leading to unfavorable side effects. Using nanocarriers represents an innovative strategy for treating CVD, enabling the personalized delivery of medications to precise locations within the cardiovascular system. Despite significant advancements in pharmacological treatments, challenges persist in effectively administering drugs to the CV system. Employing nanocarriers represents an innovative strategy for treating CVD, enabling the tailored administration of medications to precise locations within the cardiovascular system. Various studies have determined the future outlook of nanomedicines for clinical applications as nanocarrier design continues to improve, leading to enhanced drug delivery and treatment outcomes. The article focuses on the delivery systems of drugs that are effective strategies for treating cardiovascular diseases. This manuscript also seeks to explore new possibilities for how the emerging concept of nanotherapeutics could revolutionize our traditional diagnostic and treatment methods in the coming years.

A stimulus responsive microneedle-based drug delivery system for cancer therapy.

The intricate nature of the tumor microenvironment (TME) results in the inefficient delivery of anticancer drugs within tumor tissues, significantly compromising the therapeutic effect of cancer treatment. To address this issue, transdermal drug delivery microneedles (MNs) with high mechanical strength have emerged. Such MNs penetrate the skin barrier, enabling efficient drug delivery to tumor tissues. This approach enhances drug bioavailability, while also mitigating concerns such as liver and kidney toxicity associated with intravenous and oral drug administration. Notably, stimulus responsive MNs designed for drug delivery have the capacity to respond to various biological signals and pathological changes. This adaptability enables them to exert therapeutic effects within the TME, exploiting biochemical variations and tailoring treatment strategies to suit tumor characteristics. The present review surveys recent advancements in responsive MN systems. This comprehensive analysis serves as a valuable reference for the prospective application of smart MN drug delivery systems in cancer therapy.

Engineering Solutions for Drug Delivery System

This paper examines the evolution of engineering solutions in drug delivery systems, emphasizing the role of nanotechnology in overcoming current challenges in precision medicine. It addresses key challenges in drug delivery, including targeting specificity, minimizing adverse effects, and enhancing the efficiency of drug carriers. Both top-down and bottom-up engineering approaches are examined, with case studies highlighting successful applications in cancer therapy, gene delivery, and implantable devices. The paper also investigates future trends, such as smart and active delivery systems, and discusses the interdisciplinary collaboration required for these advances. By integrating material science, bioengineering, and pharmaceutical technology, this research presents innovative solutions aimed at improving therapeutic efficacy and minimizing toxicity. Keywords: Drug delivery systems, Nanotechnology, Top-down engineering, Bottom-up engineering, Gene therapy, Smart drug delivery.

Advanced biomaterials for diabetes healthcare and complication therapy: A review

With the rapid increase in the number of patients with diabetes, exploring more effective and convenient methods to lower blood sugar levels is becoming increasingly important. Biomaterials are a potential solution in this field, owing to their unique customizability and biocompatibility. These materials can be used in smart drug delivery systems to achieve precise control of insulin release, or as islet cell encapsulation materials to achieve effective transplantation of islet cells. Among these, new responsive biomaterials can automatically adjust the release of insulin according to real-time changes in blood sugar levels, thereby enabling personalized and automated treatment. In addition, biomaterials are used to develop noninvasive blood glucose monitoring technologies to further simplify diabetes management. Although these applications are still in the research or early pilot stage, their potential to improve diabetes treatment and the quality of life of patients is already evident. In this Review, we discuss the current progress, limitations, and potential of biomaterials for the treatment of diabetes and its complications.

Nanotechnology Based Alternative For The Topical Delivery Of Psoriasis

Psoriasis, a chronic autoimmune disease, is characterized by patches of abnormal skin that are red, pink, or purple, dry, itchy, and scaly. It affects people of all ages, with peak onset between 32 and 52 years old. Psoriasis is classified into three main types: vulgaris, pustular, and inverse. Novel Drug Delivery Systems (NDDS) offer innovative approaches to deliver pharmaceutical substances to the body more effectively and safely. These systems aim to increase bioavailability, maintain therapeutic drug concentrations, and minimize toxicity. Several NDDS are being used for psoriasis treatment, including: • Topical nanoparticles: These offer enhanced skin penetration, controlled release, and reduced side effects. • Liposomes: Spherical vesicles that can encapsulate drugs and deliver them to targeted areas. • Microneedle systems: Create microchannels in the skin for improved drug penetration and localized delivery. • Transdermal patches: Provide non-invasive, sustained drug delivery. • Smart drug delivery systems: Respond to specific stimuli, enabling targeted and controlled drug release

In-situ Forming Multipolymeric Glucose-Responsive Hydrogels.

Stimuli-responsive hydrogels (HGs) have shown promise for smart drug delivery applications. Specifically, glucose-responsive HGs having phenylboronic acid (PBA) functional groups are extensively pursued for insulin delivery in hyperglycemia. Current polymeric glucose-responsive HGs are cumbersome to fabricate and show a limited insulin release profile. Herein, we develop a straightforward fabrication of glucose-responsive multipolymer HGs (MPHGs) using a three-component in situ mixing. Molecular cargo, such as insulin, was loaded during the gelation. Heterobifunctional formylphenylboronic acid (FPBA) crosslinkers were used to interconnect polyvinyl alcohol (PVA) and branched polyethyleneimine (PEI) via boronate ester and imine bonds, respectively. Three positional isomers of FPBA (2FPBA, 3FPBA, and 4FPBA) resulted in HGs with distinct viscoelastic behaviors under the same conditions. HGs derived from 4FPBA exhibited more solid-like properties compared to 2FPBA and 3FPBA due to a higher crosslinking density. All the HGs exhibited glucose-responsive dissolution and release of embedded insulin cargo without disrupting the native structure. Insulin release profiles show a higher glucose-responsive release from 4FPBA-derived MPHGs. All the HGs were injectable, self-healing, and noncytotoxic below 10 μg/ml concentrations. The MPHGs developed in this study uncover new directions in creating glucose-responsive matrices for self-regulating drug delivery applications. In the future, detailed in vivo studies will be performed for clinical applications.

8-Anilino-1-naphthalenesulfonate-Conjugated Carbon-Coated Ferrite Nanodots for Fluoromagnetic Imaging, Smart Drug Delivery, and Biomolecular Sensing

Background: Superparamagnetic properties and excitation independence have been incorporated into carbon-decorated manganese ferrite nanodots (MnFe@C) to introduce an economical and safer multimodal agent for use in both T1-T2 MRI and fluorescence-based imaging to replace the conventional highly toxic heavy metal contrast agents. Methods: The surface conjugation of 8-anilino-1-naphthalenesulfonate (ANS) to MnFe@C nanodots (ANS-MnFe@C) enhances both longitudinal and transverse MRI relaxation, improves fluorescence for optical imaging, and increases protein detection sensitivity, showing higher multimodal efficacy in terms of molar relaxivity, radiant efficiencies, and fluorescence sensitivity compared to MnFe@C. Results: The band gap energy was determined using Tauc’s equation to be 3.32 eV, while a 72% quantum yield demonstrated that ANS-MnFe@C was highly fluorescent, with the linear range and association constant calculated using the Stern–Volmer relation. The synthesized ANS-MnFe@C demonstrated excellent selectivity and sensitivity for bovine serum albumin (BSA), with a nanomolar detection limit of 367.09 nM and a broad linear range from 0.015 to 0.225 mM. Conclusions: In conclusion, ANS-MnFe@C holds ease of fabrication, good biocompatibility, as assessed in A375 cells, and an effective pH-sensitive doxorubicin release profile to establish anticancer activity in lung cancer cell line (A549), highlighting its potential as an affordable therapeutic agent for multimodal imaging, drug delivery, and protein sensing.

Synthesis and evaluation of smart drugs with integrated functions for identifying and treating oxidative microenvironments associated with cellular ferroptosis

AbstractFerroptosis is a novel form of cell death driven by oxidative damage, and is implicated in various pathological conditions, including neurodegenerative diseases, retinal damage, and ischemia‐reperfusion injury of organs. Inhibiting ferroptosis has shown great promise as a therapeutic strategy for these diseases, underscoring the urgent need to develop effective ferroptosis inhibitors. Although Ferrostatin‐1 (Fer‐1) is a potent ferroptosis inhibitor, its susceptibility to oxidation and metabolic inactivation limits its clinical utility. In this study, the accumulation of peroxides and the resulting oxidative damage in the cellular microenvironment during ferroptosis were utilized to design Ferrostatin‐1 prodrugs with reactive oxygen species‐responsive features. This approach led to the development of a series of ferroptosis inhibitors that were capable of recognizing oxidative damage in diseased areas, allowing for targeted release and improved stability. The novel compounds demonstrated significant inhibitory effects and selectivity against RSL‐3‐induced ferroptosis in HK‐2 cells, with compound a1 exhibiting an EC50 of 15.4 ± 0.7 μM, outperforming Fer‐1. These compounds effectively identify the oxidative microenvironment associated with ferroptosis, enabling the targeted release of Fer‐1, which prevents lipid peroxide accumulation and inhibits ferroptosis. This strategy holds promise for treating diseases related to ferroptosis, offering a targeted and intelligent therapeutic approach.

Cell membrane camouflaged Cu-doped mesoporous polydopamine for combined CT/PTT/CDT synergistic treatment of breast cancer

Currently, traditional monotherapy for cancer often results in indiscriminate attacks on the body, leading to the emergence of new health problems. To confront these challenges, multimodal combination therapy has become necessary. However, how to develop new smart nanomaterials through green synthesis methods, delivering drugs while simultaneously synergizing multimodal combination therapies for tumor treatment, remains a topic of great significance. In this study, a biomimetic composite nanomaterial (RM-Cu/P) composed of mesoporous polydopamine (MPDA) as the core and red blood cell membranes (RBCMs) as the shell was synthesized as a drug carrier to deliver doxorubicin (DOX) while achieving synergistic chemotherapy, photothermal and chemodynamic therapy (CT/PTT/CDT). Herein, the nanoparticles were extensively characterized to examine their morphological characteristics, elemental composition, and drug-carrying capacity. Notably, the coating of RBCM reduced the toxicity of the RM-Cu/P@DOX nanoparticles, improved their targeting ability and prolonged their circulation time in vivo. The Cu-doped nanoparticles were capable of initiating a Fenton-like reaction to generate reactive oxygen species (ROS) for CDT, while the photothermal conversion efficiency (η) reached 45.20 % under NIR laser irradiation. Subsequently, the particles were examined by in vivo and in vitro experimental studies in cytotoxicity, cellular uptake, ROS levels, lysosomal escape, and mouse tumor model to evaluate their potential application in antitumor. Compared with monotherapy, the RM-Cu/P@DOX nanoparticles had multiple-stimulation response properties under redox, pH, and NIR, which exhibited the advantage of combined trimodal therapy, resulting in remarkable synergistic antitumor efficacy. In conclusion, this innovative platform exhibited promising applications in smart drug delivery and synergistic treatment of cancer.

A Brief Review on Smart Drug Design in Favour of Improving Health Indicator

A Brief Review on Smart Drug Design in Favour of Improving Health Indicator

Antitumor properties of bromelain loaded trastuzumab conjugated niosomes in HER2+ breast cancer cells

There are multiple forms of treatment for cancer treatment, but since the treatment process also damages healthy cells. Accordingly, in recent years, in the light of nanotechnological studies, cancer cell targeted drugs known as smart drugs have attracted attention. Niosome is one of the preferred nanoparticle systems in these studies. Bromelain is a protease mixture obtained from the pineapple stem or fruit. In recent years, it has been shown in many cell types that it has anticancer properties due to its proteolytic activity. In this study, bromelain was encapsulated into niosomes with 32 ± 2.9 % efficiency for the treatment of breast cancer, which is the most common type of cancer in women. Specific targeting of niosome-encapsulated bromelain to HER2+ SKBR-3 cell line was performed by trastuzumab (herceptin) conjugation. DLS, FTIR, XPS, TEM were used for particle characterization. Niosomes (Nio) showed particle size of 134.3 ± 8.1 nm, Bromelain loaded niosomes (Nio-Br) showed particle size of 165.6 ± 11.5 nm. As a result of TEM analysis, it was shown that morphologically spherical and targeted sizes of niosomes of approximately 100 nm were synthesized. FTIR and XPS analyzes were performed to confirm pegylation and trastuzumab conjugation. Cytotoxicity and apoptosis studies of Nio-Br, Nio-Br-PEG-Tra, Tra samples carried out in SKBR-3 and MDA-MB-231 cell lines. Determined IC50 values of final product on SKBR-3 and MDA-MB-231 cell lines respectively 77.51 ± 5.39 μg/mL and 238.1 ± 16.62 μg/mL. As a result of in vitro studies, final product is more toxic on HER2+ SKBR-3 cell line thanks to trastuzumab in structure. At the same time final product has more apoptotic effect connected to toxic characteristic. Formed molecule in this study was designed for HER2+ breast cancer cells. According to obtained in vitro experiment results, this designed molecule has potential to be drug delivery system for HER2+ breast cancer.

Tuning the Stability and Kinetics of Dioxazaborocanes.

We investigated the equilibrium reaction of boronic acid (BA), diethanolamines (DEA), and 1,3,6,2-dioxazaborocanes (DOAB) in aqueous solutions, both theoretically and experimentally. Our findings show that the association constant can be adjusted by substituting BA and DEA derivatives, ranging from 100 to 103 M-1, exhibiting a bell-shaped pH dependency. The highest stability was achieved when the pKa values of DEA and BA were closely matched. This approach enabled the preparation of a highly stable DOAB under physiological conditions. Furthermore, the hydrolysis kinetics of DOABs were controllable over a range of five orders of magnitude based on the substituent's steric effect. In the slowest case, this resulted in quasi-static stability with only 1% cleavage in the first hour, followed by a week-long cleavage period to reach equilibrium. These insights could establish a unique chemistry platform for designing scheduled cleavability on a day-to-week timescale, relevant to protein engineering, immunotherapy, and other smart drug delivery applications.

Titanium Dioxide Nanomaterials: Progress in Synthesis and Application in Drug Delivery.

Background: Recent developments in nanotechnology have provided efficient and promising methods for the treatment of diseases to achieve better therapeutic results and lower side effects. Titanium dioxide (TiO2) nanomaterials are emerging inorganic nanomaterials with excellent properties such as low toxicity and easy functionalization. TiO2 with special nanostructures can be used as delivery vehicles for drugs, genes and antigens for various therapeutic options. The exploration of TiO2-based drug delivery systems shows great promise for translating nanotechnology into clinical applications; Methods: Comprehensive data on titanium dioxide were collected from reputable online databases including PubMed, GreenMedical, Web of Science, Google Scholar, China National Knowledge Infrastructure Database, and National Intellectual Property Administration; Results: In this review, we discuss the synthesis pathways and functionalization strategies of TiO2. Recent advances of TiO2 as a drug delivery system, including sustained and controlled drug release delivery systems were introduced. Rigorous long-term systematic toxicity assessment is an extremely critical step in application to the clinic, and toxicity is still a problem that needs to be closely monitored; Conclusions: Despite the great progress made in TiO2-based smart systems, there is still a great potential for development. Future research may focus on developing dual-reaction delivery systems and single-reaction delivery systems like redox and enzyme reactions. Undertaking thorough in vivo investigations is necessary prior to initiating human clinical trials. The high versatility of these smart drug delivery systems will drive the development of novel nanomedicines for personalized treatment and diagnosis of many diseases with poor prognosis.

Nanoscale fluconazole-constructed metal-organic frameworks with smart drug release for eradication of Candida biofilms in vulvovaginitis infection

Fungal infections associated with oral, gynecological, and skin ailments pose significant clinical challenges. The presence of biofilms often hampers the efficacy of conventional antifungal drugs owing to the complex microenvironment they create. In this study, the widely used antifungal medication fluconazole is utilized as a foundational component to be incorporated into zinc 2-methylimidazolate frameworks, resulting in the synthesis of nanoscale fluconazole-constructed metal-organic frameworks (F-ZIF). The F-ZIF is constructed through coordination interactions between zinc and fluconazole, retaining the structure and pH-responsiveness of the zinc 2-methylimidazolate framework. The pH-responsiveness F-ZIF makes sure the fluconazole can be released in acidic biofilm, which prevents the undesired release in healthy tissue, resulting in good biocompatibility both in vitro and in vivo. The in vitro studies demonstrated that F-ZIF exhibits enhanced efficacy in eradicating fungal pathogens in their biofilm growth state compared with the free fluconazole. Furthermore, in vivo experiments reveal the better effectiveness of F-ZIF in treating Candida albicans-induced vulvovaginal candidiasis, and less infection-related inflammation was observed. Hence, the one-port synthetic F-ZIF presents a promising solution for addressing fungal biofilm-related infections.

Versatile hydrogel drug carrier loading with peptide-carbon dots conjugates for efficient targeting and synergistic suppression of breast cancer cell

Breast cancer become the most prevalent malignancy and is rising up to the first leading cause of cancer-related mortality among the female people globally. Approaches for safe, specific targeting and efficient inhibition of breast cancer cells, are urgently demanded for lifting the survival rate of breast tumor-bearing patients. Herein, a versatile hydrogel drug carrier consisting of doxorubicin (DOX)-loaded hydrogel microsphere and carbon dots (CDs)-loaded peptide nanowires (DOX@PEG/PNFs-CDs) was constructed, presenting specific targeting and synergistic anti-cancer cell potencies. The hydrogel PEG microspheres with a rich porous structure benefited the drug loading efficiency, demonstrating good biodegradability and higher drug release efficiency at acidic environment. Benefiting from the RGD group of the peptide nanowires, the drug-loaded system specific targeted onto the MDA-MB-231 cells, subsequently promoting the synergistic inhibition of the cancer cell growth by DOX and metformin derived CDs. This all-in-one smart drug carrier post a promising strategy for breast cancer treatment.

Dual Chemotherapeutic Loading in Oxalate Transferrin-Conjugated Polymersomes Incorporated into Chitosan Hydrogels for Site-Specific Targeting of Melanoma Cells.

In this work, we developed a smart drug delivery system composed of poly (ethylene glycol)-block-poly (ε-caprolactone) (PEG-PCL)-based polymersomes (Ps) loaded with doxorubicin (DOX) and vemurafenib (VEM). To enhance targeted delivery to malignant melanoma cells, these drug-loaded nanovesicles were conjugated to the oxalate transferrin variant (oxalate Tf) and incorporated into three-dimensional chitosan hydrogels. This innovative approach represents the first application of oxalate Tf for the precision delivery of drug-loaded polymersomes within a semi-solid dosage form based on chitosan hydrogels. These resulting semi-solids exhibited a sustained release profile for both encapsulated drugs. To evaluate their potency, we compared the cytotoxicity of native Tf-Ps with oxalate Tf-Ps. Notably, the oxalate Tf-Ps demonstrated a 3-fold decrease in cell viability against melanoma cells compared to normal cells and were 1.6-fold more potent than native Tf-Ps, indicating the greater potency of this nanoformulation. These findings suggest that dual-drug delivery using an oxalate-Tf-targeting ligand significantly enhances the drug delivery efficiency of Tf-conjugated nanovesicles and offers a promising strategy to overcome the challenge of multidrug resistance in melanoma therapy.

A novel zingerone-loaded zinc MOF coated by niosome nanocomposites to enhance antimicrobial properties and apoptosis in breast cancer cells

Breast cancer (BC) is a prevalent malignancy among women, presenting significant health risks. The development of targeted smart drug delivery has greatly enhanced tumor therapy and antibacterial treatments. In this study, we fabricated a novel Zn-metal organic framework (Zn-MOF) at the nanoscale using an oil bath technique and loaded it with zingerone (ZG) and coated with niosomes (Nio) to form ZG-Zn-MOF@Nio, designed for both anti-microbial and anticancer purposes. We investigated the anti-microbial activity by assessing the minimum inhibitory concentration and zone of inhibition by zingerone, Zn-MOF, and ZG-Zn-MOF@Nio. Scanning electron microscopy (SEM) analysis revealed that the synthesized ZG-Zn-MOF@Nio exhibited well-defined rod and cilia-like morphology. Transmission electron microscopy (TEM) images showed ZG-Zn-MOF@Nio nanoparticles (NPs) with a spherical-like shape and an average diameter of 0.34 µm and a zeta potential of (+22 mV). The encapsulation efficiency of zingerone into Zn-MOF was up to 92.56 %, with a loading capacity of 11.55 % (*P<0.05). Four kinetic models were used to analyze the release mechanism of zingerone at pH 6.5, with the zero-order model showing an excellent fit (R2 = 0.9985, *P<0.05). Additionally, the minimum inhibitory concentration of synthesized zingerone, Zn-MOF, and ZG-Zn-MOF@Nio NPs were tested against Gram-positive Bacillus subtilis (B. subtilis) and Staphylococcus aureus (S. aures), as well as the gram-negative strains Escherichia coli (E. coli) and Pseudomonas aeruginosa (P. aeruginosa). In vitro test revealed that the minimum inhibitory concentration of ZG-Zn-MOF@Nio was 31.25 μg/mL against S. aures and B. subtilis, and 62.5 μg/mL against P. aeruginosa and E.coli were. The MCF-7 cell line was utilized as in-vitro model. The MTT assay demonstrated significant cytotoxicity of ZG-Zn-MOF@Nio against MCF-7 cells, with an IC50 values of 46.2 µg/mL, inducing apoptosis in 94.8 % of the cells.

Towards the preparation of smart drug delivery platforms for colorectal cancer therapy: Biocompatible and targeted mesoporous silica nanoparticles with the deferiprone-copper complex gatekeeper

BackgroundAchieving smart drug release and preventing premature leakage throughout the delivery journey are two crucial factors that are essential to take into account in the design of nanocarriers. Mesoporous silica nanoparticles (MSNs) can be modified with gatekeeper molecules to achieve controlled release behavior, making them highly promising nanocarriers for smart drug delivery purposes. MethodsHerein, we introduced a novel gatekeeper in the form of an inverted umbrella, consisting of a deferiprone (DFP)-copper complex, which was strategically immobilized on the surface of MSNs to facilitate smart and controlled release of doxorubicin (DOX) within tumor cells. Polyethylene glycol (PEG) polymer and aptamer were further added onto the surface of the nanocarrier to enhance its biocompatibility, and targeting capabilities. The physicochemical characteristics of the targeted nanoplatform, Apt-PEG-DOX@GNP, were investigated, and its anti-cancer effect was evaluated against C26 cells and CHO cells to assess its specificity. In order to evaluate the anti-tumor efficacy, possible side effects, and biodistribution of the prepared nanocarriers, the in vivo experiment was carried out on BALB/c mice bearing colorectal tumors. ResultsThe substantial surface area of MSNs, measuring 339 m2/g, facilitated effective encapsulation of DOX with a maximum loading 23 % ± 2.05. Preparation of Apt-PEG-DOX@GNP yielded uniform particles with an average diameter of 144.73 ± 11.29 nm. The Apt-PEG-DOX@GNP demonstrated iron-dependent release behaviors, wherein the cleavage of DFP−COOH-Cu(II) bonds decorating the silica nanoparticles occurred asynchronously, leading to the formation of new DFP−COOH-Fe(II) bonds for the subsequent release of DOX. The in vivo experiments revealed that the biocompatible nanocarriers displayed targeted toxicity towards C26 tumor-bearing BALB/c mice, resulting in minimal side effects. ConclusionOur prepared novel nanoplatforms showed promising potential for targeted treatment of colorectal cancer and precise control over the drug release.

The electro-responsive nanoliposome as an on-demand drug delivery platform for epilepsy treatment

Nano-based drug delivery systems are regarded as a promising tool for efficient epilepsy treatment and seizure medication with the least general side effects and socioeconomic challenges. In the current study, we have designed a smart nanoscale drug delivery platform and applied it in the kindling model of epilepsy that is triggered rapidly by epileptic discharges and releases anticonvulsant drugs in situ, such as carbamazepine (CBZ). The CBZ-loaded electroactive ferrocene nanoliposomes had an average diameter of 100.6 nm, a surface charge of −7.08 mV, and high drug encapsulation efficiency (85.4 %). A significant increase in liposome size was observed in response to direct current (50–500 μA) application. This liposome-based drug delivery system can release CBZ at a fast rate in response to both direct current and pulsatile electrical stimulation in vitro. The CBZ-liposome can release the anticonvulsant drug upon epileptiform activity in the kindled rat model and can decline electrographic and behavioral seizure activity in response to electrical stimulation of the hippocampus with an initially subconvulsive current. With satisfactory biosafety results, this “smart” nanocarrier has promising potential as an effective and safe drug delivery system to improve the therapeutic index of antiepileptic drugs.

Review on Nanogel as a Novel Platform for Smart Drug Delivery System

One of the most popular applications of nanotechnology in both topical and internal medicine administration to the body is nanogel technology. The materials comprising the nanoparticulate frameworks are less than 100 nm in a single measurement. The goal of this review paper is to provide a concise overview of the most recent developments in the nanogel medicine delivery framework with regard to drug loading and swelling. It categorises according to links (chemical and physical) and responding behaviour. This article is to give a broad overview of nanogels, their innovative use in many contexts, and current synthesis techniques. NGs use drugs for a variety of reasons, including diagnostics, gene targeting, organ targeting, and many more. Different pulmonary, nasal, transdermal, intra-ocular, oral, and parenteral routes can be used to give NGs. The primary goals of this review are to present broad details on NGs, their characteristics, multiple categories, medication targeting strategies, kinds of drug delivery systems, assessment techniques, and cutting-edge uses for NGs in depth. Keywords: Nanogel, DLS, CD, mechanism of drug release, classification, application